CoChat
Sign Up
Cited by 421Antifungal resistance and susceptibilityYeasts and Rust Fungi StudiesFungal Infections and Studies

Candida auris : The recent emergence of a multidrug-resistant fungal pathogen

Open access
Forsberg, Kaitlin, Woodworth, Kate, Walters, Maroya, Berkow, Elizabeth L, Jackson, Brendan, Chiller, Tom, Vallabhaneni, Snigdha·2019·Medical Mycology
DOI 10.1093/mmy/myy054
Open this paper in CoChat — free accountOpen PDF

Abstract

Candida auris is an emerging multidrug-resistant yeast that causes serious invasive infections with high mortality. It was first discovered in 2009, and since then, individual cases or outbreaks have been reported from over 20 countries on five continents. Controlling C. auris is challenging for several reasons: (1) it is resistant to multiple classes of antifungals, (2) it can be misidentified as other yeasts by commonly available identification methods, and (3) because of its ability to colonize patients perhaps indefinitely and persist in the healthcare environment, it can spread between patients in healthcare settings. The transmissibility and high levels of antifungal resistance that are characteristic of C. auris set it apart from most other Candida species. A robust response that involves the laboratory, clinicians, and public health agencies is needed to identify and treat infections and prevent transmission. We review the global emergence, biology, challenges with laboratory identification, drug resistance, clinical manifestations, treatment, risk factors for infection, transmission, and control of C. auris.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/mmy/myy054

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • C. auris shows pronounced adhesion to abiotic and biotic surfaces such as human skin, facilitating human-to-human transmission in clinical settings.

    “C. auris shows pronounced adhesion to abiotic and biotic surfaces such as human skin, thus facilitating human-to-human transmission in clinical settings (20).”

    From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [20]

    The Biology and morphology section says C. auris biofilms provide a mechanism of adherence to surfaces, but cautions that it may attach less readily to catheter material than species with more robust biofilms. The Patients can be colonized section reports a predilection for skin, and Transmission between patients documents spread in healthcare settings. These passages support surface adherence, skin colonization, and clinical transmission, but not the claim of pronounced adhesion to both abiotic surfaces and human skin as the cause of that transmission. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • C. auris is a major cause of multidrug-resistant, healthcare-associated candidiasis with mortality rates of 30-45%.

    “C. auris has burst onto the scene as a major cause of MDR, healthcare-associated candidiasis with mortality rates ranging from 30 to 45% [10, 11].”

    From Investigational Agents for the Treatment of Resistant Yeasts and Molds (2021) · cites this paper as [11]

  • In C. auris, reported resistance rates are fluconazole 90-93%, amphotericin B 15-30%, and echinocandin 2-10%.

    “Various studies have reported fluconazole resistance 90–93%, amphotericin B (AmB) resistance 15–30%, and echinocandin resistance 2–10% [11].”

    From Investigational Agents for the Treatment of Resistant Yeasts and Molds (2021) · cites this paper as [11]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Britz E, Govender NP. Global emergence of a multi-drug resistant fungal pathogen, Candida auris. South Afr J Infect Dis. 2016; 31: 3-4.
  2. British Columbia Centre for Disease Control. Case reports of public health sig- nificance: first Candida auris case identified in BC. Laboratory Trends. October 2017; 2017: 4.
  3. Munoz-Price LS, Hayden MK, Lolans K et al. Successful control of an out- break of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol. 2010; 31: 341-347.

Cited by

Sorted by citations

Related

Authors
Forsberg, K., Woodworth, K., Walters, M., Berkow, E. L., Jackson, B., Chiller, T., & Vallabhaneni, S.
Affiliations
Centers for Disease Control and Prevention (US)
Corresponding author
Vallabhaneni, Snigdha
ORCID
Venue
Medical Mycology
Publisher
Oxford University Press (OUP)
Published
2018-07-31
Volume
57
Issue
1
Pages
1-12
ISSN
  • 0268-1218 (ISSN-L)
  • 1369-3786
  • 1460-2709
DOI
10.1093/mmy/myy054
OpenAlex
W2885246726
Cited by
421
References
83
Citations by year
2026: 38 · 2025: 63 · 2024: 46 · 2023: 54 · 2022: 51 · 2021: 69 · 2020: 62 · 2019: 34 · 2018: 4
FWCI
6.19
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • Medical Mycology (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
Centers for Disease Control and Prevention
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords
Candida auris, multidrug resistance, antifungal resistance, emerging fungal pathogens, invasive candidiasis, nosocomial infections, transmission control, risk factors, clinical features, antifungal therapy
MeSH terms
Antifungal Agents, Candida, Candidiasis, Cross Infection, Disease Outbreaks, Risk Factors, Global Health, Drug Resistance, Multiple, Fungal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review